Safety and Efficacy Study of Abdominal Aortic Aneurysm Stent Graft System

Abdominal Aortic Aneurysm Clinical Trial

Official title:

Safety and Efficacy Study of Abdominal Aortic Aneurysm Stent Graft System for Infrarenal Abdominal Aortic Aneurysm: A Prospective, Multi-center, Objective Performance Criteria Clinical Trial

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03687489
• Other study ID #: LTAAA-01
• Status: Active, not recruiting
• Phase: N/A
• Start date: September 30, 2018
• Est. completion date: March 31, 2025

Study information

• Verified date: December 2019
• Source: Lifetech Scientific (Shenzhen) Co., Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A prospective, multi-centre, objective performance criteria clinical trial to evaluate the safety and efficacy of Abdominal Aortic Aneurysm Stent Graft System manufactured by Lifetech Scientific (Shenzhen) Co., LTD. for the infrarenal abdominal aortic aneurysm.

Description:

This clinical trial was conducted in a qualified clinical trial institution. Investigators will use Abdominal Aortic Aneurysm Stent Graft System manufactured by Lifetech Scientific (Shenzhen) Co., LTD. to treat patients with Infrarenal Abdominal Aortic Aneurysm. This is a Prospective, Multi-center, Objective Performance Criteria Clinical Trial. It is expected to submit to the ethics committee of the lead unit for review in March 2018, and complete the implantation of 156 patients in 22 centres nationwide within 12 months, and interim follow-up was conducted before discharge, 30 days after surgery, 6 months after surgery and 12 months after surgery, long-term follow-up will be performed at 24 months postoperatively, 36 months postoperatively, 48 months postoperatively and 60 months postoperatively.

This trial will evaluate whether the device reached the primary safety endpoint and primary efficacy endpoint through two primary endpoint indicators: the incidence of major adverse events (MAE) within 30 days and the success rate of abdominal aortic aneurysm treatment 12 months after surgery. This trail will evaluate whether the device reached the secondary safety endpoint and primary efficacy endpoint through several secondary endpoint indicators: Perioperative (intraoperative to postoperative 30 days) delivery related complications incidence rate (including the transabdominal surgery caused by intraoperative conveyors, the hemorrhage in the middle iliac artery, the hemorrhage in the femoral artery at the puncture site, the hematoma and the pseudoaneurysm), the incidence of acute lower limb ischemia before discharge and 30 days after surgery, all-cause mortality at 6 months, 12 months and 2-5 years after surgery, abdominal aortic aneurysm-related mortality at 6 months, 12 months and 2-5 years after surgery, the incidence of severe adverse events (SAE) at 6 months, 12 months and 2-5 years after surgery, the incidence of the device-related adverse events (AE) at 6 months, 12 months and 2-5 years after surgery, the incidence of type I or type III leakage at 6 months, 12 months after surgery, the incidence of displacement of Abdominal Aortic Aneurysm Stent at 6 months, 12 months after surgery and the incidence of conversion from abdominal aortic aneurysm treatment to open surgery or secondary surgery intervention at 6 months, 12 months and 2-5 years after surgery. According to the guidelines for clinical trials of aortic stent system, the sponsor will apply for CFDA listing registration after completing a 12-month primary endpoint assessment. According to the guidelines for clinical trials of aortic covered stent system, the sponsor will apply for CFDA listing registration after completing a 12-month primary endpoint assessment, and annually follow-up will be conducted until the fifth year for the long-term efficacy observation.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 156
• Est. completion date: March 31, 2025
• Est. primary completion date: November 30, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 85 Years

Eligibility

Inclusion Criteria:

• 1. Patients aged greater than 18 years old and less than 85 years old, regardless of gender.

2. Patients who can understand the purpose of the trial, voluntarily participate in and sign the informed consent, and are willing to complete the follow-up according to the requirements of the protocol.

3. Patients diagnosed with Infrarenal Abdominal Aortic Aneurysm and should meet at least one of the following conditions:

1. The maximum diameter of abdominal aortic aneurysm =50mm in male patients, or the maximum diameter of abdominal aortic aneurysm =45mm in female patients.

2. The maximum diameter of abdominal aortic aneurysm =40mm and the diameter increased by more than 5mm in the last 6 months (In this case, the diameter data of abdominal aortic aneurysm should be traceable within 6 months).

3. The abdominal aortic aneurysm compresses vital organs and causes symptoms (such as abdominal pain, lower back pain, etc.) 4. The range of proximal aneurysm neck diameter of the abdominal aortic aneurysm is between 17mm to 32mm.

5. The length of the proximal aneurysm neck of abdominal aortic aneurysm=10mm, and the angle of the proximal aneurysm neck =75 °.

6. The range of the diameter of the iliac artery anchoring area is between 8mm to 22mm.

7.The length of the iliac artery anchoring area=15mm.

8. The patient has a suitable iliac and femoral artery approach.

Exclusion Criteria:

• 1. Patients with severe stenosis, calcification, or mural thrombus in the anchoring area of the stent and easily lead to incomplete stent apposition.

2. Patients with rupture of an abdominal aortic aneurysm or threatened rupture.

3. Patients with abdominal aortic dissection.

4. Patients with mycotic or infectious abdominal aortic aneurysms.

5. Patients with a history of myocardial infarction or unstable angina pectoris for 6 months. Characteristics of unstable angina pectoris: angina symptoms gradually increased, new onset of rest or night angina pectoris or occurrence of angina prolonged.

6. Patients with any transient ischemic attack (TIA) or ischemic stroke within 3 months.

7. Patients with a history of allergy to contrast media, stents and conveyor materials (including nickel and titanium, polyester, PTFE, and nylon polymer materials).

8. A patient with connective tissue diseases such as Marfan syndrome, Eaton syndrome, or Bessel's disease.

9. Patients with liver dysfunction: Alanine transaminase (ALT) or Aspartate transaminase (AST) were five times higher than the normal upper limit;serum total bilirubin (STB) was two times higher than the normal upper limit.

10. Patients with renal dysfunction: Serum creatinine (Cr) was two times higher than the normal upper limit.

11. Life expectancy is less than one year.

12. Patients with major organ failure or other serious diseases;

13. Patients who were not suitable for endovascular treatment, judged by the investigator.

14. Pregnant or lactating women or women who plan to get pregnant.

15. The patients participated in other clinical trials and did not come out of the group or withdraw within the first 3 months of the screening period of this trial.

Related Conditions & MeSH terms

• Abdominal Aortic Aneurysm
• Aneurysm
• Aortic Aneurysm
• Aortic Aneurysm, Abdominal

Intervention

Device:
• Abdominal Aortic Aneurysm Stent Graft System
Abdominal aortic bifurcation stent and iliac artery extension stent were preloaded into abdominal aortic bifurcation stent transporter and iliac artery extension stent transporter, respectively. In the operation, the abdominal aorta bifurcation stent and the iliac artery extension stent will be delivered to the corresponding lesion position of the abdominal iliac artery and release. The abdominal aortic bifurcation stent and the iliac artery extension stent will form a whole through docking and thereby reducing the risk of rupture of an infrarenal abdominal aortic aneurysm due to the shock of blood flow.

Locations

Country	Name	City	State
China	Chinese PLA General Hospita	Beijing	Beijing
China	The Second Xiangya Hospital of Central South University	Changsha	Hunan
China	Xiangya Hospital Central South University	Changsha	Hunan
China	The First Affiliated Hospital of Fujian Medical University	Fuzhou	Fujian
China	The Frist Affiliated Hospital, Zhejiang University	Hangzhou	Zhejiang
China	The Second Affiliated Hospital of Zhejiang University School of Medicine	Hangzhou	Zhejiang
China	Qilu Hospital of Shandong University	Jinan	Shandong
China	Shandong Provincial Hospital	Jinan	Shandong
China	Frist Affiliated Hospital of Kunming Medical University	Kunming	Yunnan
China	Yan'an Hospital of Kunming City	Kunming	Yunnan
China	The Frist Hospital of Lanzhou University	Lanzhou	Gansu
China	Liuzhou General Hospital	Liuzhou	Guangxi
China	The Affiliated Hospital of Southwest Medical University	Luzhou	Sichuan
China	Jiangsu Province Hospital	Nanjing	Jiangsu
China	The First Affiliated Hospital of Guangxi Medical University	Nanning	Guangxi
China	Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine	Shanghai	Shanghai
China	The Second Hospital of Heibei Medical University	Shijiazhuang	Hebei
China	Tianjing Medical University General Hospital	Tianjin	Tianjin
China	The First Affiliated Hospital of Xinjiang Medical University	Ürümqi	Xinjiang
China	Renming Hospital of Wuhan University	Wuhan	Hubei
China	Xijing Hospital, The Fourth Military Medical University	Xi'an	Shanxi
China	General Hospital of Ningxia Medical University	Yinchuan	Ningxia

Sponsors (1)

Lead Sponsor	Collaborator
Lifetech Scientific (Shenzhen) Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The success rate of abdominal aortic aneurysm treatment	A successful abdominal aortic aneurysm treatment is a composite index and refers to the following criteria simultaneously: the immediate technical success (the immediate technical success refers to the delivery system is successfully delivered to a predetermined location, the abdominal aortic stent is successfully deployed, and the transporter can be safely withdrawn from the body).; the increase of maximum diameter of abdominal aortic aneurysm at the 12th month after surgery =5mm, compared with that before surgery.; The displacement of anterior abdominal aortic stent was no more than 10mm at the 12th month after the operation from the location before discharge.; No type I or type III leakage requiring additional intervention occurred 12 months after surgery? No abdominal aortic aneurysm rupture within 12 months after surgery.	12 months after operation
Secondary	The incidence of Major Adverse Event (MAE)	Major Adverse Event (MAE) is defined as all-cause death, myocardial infarction, renal failure, respiratory failure, paraplegia, stroke, and intestinal ischemia.	30 days after surgery
Secondary	Incidence of type I or III leakage	Type I leakage is also known as peripheral leakage or graft related leakage, which refers to internal leakage resulting from the inability of stent-type blood vessels to adhere closely to an autologous blood vessel, and the blood flow continues to flow into the aneurysm cavity, including proximal type I and distal type I leakage. Type III leakage refers to leakage caused by the failure of stent-type vessels to bind themselves tightly or the rupture of artificial vessels, and the blood flow continues to flow into the aneurysm cavity.	6 months, 12 months after surgery
Secondary	The incidence of abdominal aortic stent displacement	The displacement refers to the position of abdominal aorta stents of postoperative follow-up are displaced more than 10 mm from the before discharge position.	6 months, 12 months after surgery
Secondary	Operation efficacy - incidence of conversion from abdominal aortic aneurysm treatment to open surgery or secondary surgery	The incidence of conversion from abdominal aortic aneurysm treatment to open surgery or secondary surgery intervention.	6 months, 12 months and 2-5 years after surgery.
Secondary	The incidence rate of perioperative delivery related complications	Perioperative period refers to intraoperative time to 30 days postoperative. Delivery related complications incidence including he transabdominal surgery caused by intraoperative conveyors, the hemorrhage in the middle iliac artery, the hemorrhage in the femoral artery at the puncture site, the hematoma and the pseudoaneurysm.	intraoperative and postoperative 30 days.
Secondary	The incidence of Acute lower limb ischemia.	The incidence of acute lower limb ischemia.	Before discharge and 30 days after surgery
Secondary	All-cause mortality	All-cause mortality evaluates at 6 months, 12 months and 2-5 years after surgery	6 months, 12 months and 2-5 years after surgery
Secondary	Disease related mortality	Abdominal aortic aneurysm-related mortality evaluates at 6 months, 12 months and 2-5 years after surgery.	6 months, 12 months and 2-5 years after surgery
Secondary	Severe adverse events (SAE)	The incidence of severe adverse events (SAE). According to the ISO 14155 SAE refers to; led to death,; led to serious deterioration in the health of the subject, that either resulted in; a life-threatening illness or injury, or; a permanent impairment of a body structure or a body function, or; in-patient or prolonged hospitalization, or; medical or surgical intervention to prevent life-threatening illness or injury or permanent impairment to a body structure or a body function,; led to foetal distress, foetal death or a congenital abnormality or birth defect	6 months, 12 months and 2-5 years after surgery
Secondary	Device-related adverse effects (AE)	The incidence of the device-related adverse effects (AE), according to the ISO14155, adverse device effect that has resulted in any of the consequences characteristic of a serious adverse event.	6 months, 12 months and 2-5 years after surgery